Moderna, Inc. reported second quarter revenues of $142 million for 2025, a 41% decrease from $241 million in the same quarter of 2024, primarily due to lower COVID vaccine sales. The company recorded a GAAP net loss of $800 million, or $(2.13) per share, compared to a net loss of $(1.3) billion, or $(3.33) per share in Q2 2024. Moderna updated its projected revenue range for 2025 to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end due to delayed deliveries. The company expects to maintain a year-end cash balance of approximately $6 billion and has improved its expected operating expenses for the year by about $400 million to a range of $5.9 to $6.1 billion.
In addition to financial results, Moderna announced three recent FDA approvals and positive Phase 3 results for its seasonal influenza vaccine. The company reported $114 million in Spikevax sales for Q2 2025, with expectations for increased demand in the latter half of the year. R&D expenses decreased by 43% to $700 million, attributed to reduced clinical trial and manufacturing costs. Moderna also announced a workforce reduction of about 10% and highlighted ongoing advancements in its pipeline, including vaccines for RSV, norovirus, and various oncology therapeutics.
linkAug 01, 2025 07:02:12
Moderna, Inc. announced its financial results for the first quarter of 2025, reporting revenues of $108 million and a GAAP net loss of $1.0 billion, resulting in a loss per share of $2.52. The revenue decline from $167 million in the same quarter of 2024 was attributed to lower vaccination rates and a shift in COVID-19 demand to a seasonal market. The company reaffirmed its expected revenue range for 2025 of $1.5 to $2.5 billion and projected a year-end cash balance of approximately $6 billion.
The company is also implementing cost reductions, aiming to decrease operating expenses by $1.4 to $1.7 billion by 2027. Moderna is advancing up to 10 products towards approval, with a focus on oncology candidates and respiratory vaccines. Recent sales included $84 million from its COVID-19 vaccine, Spikevax®, and $2 million from its RSV vaccine, mRESVIA®. The company's cash position as of March 31, 2025, stood at $8.4 billion, down from $9.5 billion at the end of 2024.
linkMay 01, 2025 06:31:33
Moderna reported fourth quarter revenues of $1.0 billion, a significant decline from $2.8 billion in the same period last year, primarily due to lower sales of its COVID-19 vaccine. The company faced a GAAP net loss of $(1.1) billion, which included non-cash charges related to manufacturing resizing, and a loss per share of $(2.91), compared to earnings per share of $0.55 in Q4 2023. For the full year 2024, total revenues were $3.2 billion, down from $6.8 billion in 2023, reflecting a shift to a seasonal market for COVID-19 vaccines and reduced sales volumes in international markets. However, the company ended the year with a cash position of $9.5 billion, an increase from $9.2 billion at the end of the previous quarter, indicating some liquidity improvement amid operational challenges.
In terms of operational updates, Moderna successfully submitted three investigational mRNA products for regulatory approval, including a next-generation COVID vaccine and an RSV vaccine, which could support future revenue streams. The company also achieved a 27% reduction in costs compared to the previous year, with significant decreases in research and development as well as selling, general, and administrative expenses. However, the overall net loss for 2024 was $(3.6) billion, an improvement from the $(4.7) billion loss in 2023, but the decline in revenues and ongoing operational challenges highlight the need for continued focus on cost management and product approvals in the upcoming year.
linkFeb 14, 2025 06:30:34
Moderna announced that it achieved product sales of approximately $3.0 to $3.1 billion for 2024, with a significant cash balance of about $9.5 billion at year-end. The company plans to reduce cash costs by $1.0 billion in 2025 and anticipates a projected revenue range of $1.5 to $2.5 billion for that year, largely driven by vaccine sales. The company is focusing on approvals across ten prioritized programs, including its RSV vaccine and next-generation COVID-19 vaccine.
On the downside, Moderna updated its expected ending cash balance for 2025 to approximately $6.0 billion, indicating a decrease from its current balance. Additionally, the Data Safety Monitoring Board for its cytomegalovirus vaccine indicated that early efficacy criteria were not met, although the study will continue. The company faces uncertainties in its pipeline with potential delays in data readouts and approvals, which could impact future revenue.
linkJan 13, 2025 07:03:24
Moderna's third quarter of 2024 saw total revenues of $1.9 billion, marking a slight increase from $1.8 billion in the same period last year. The company reported a net income of $13 million, a significant turnaround from a net loss of $3.6 billion in the third quarter of 2023. Key drivers for this growth included strong sales of its updated COVID-19 vaccine, Spikevax®, which generated $1.8 billion in revenue, and a notable decrease in costs associated with sales and operational efficiencies. The company also initiated two pivotal Phase 3 trials for new mRNA vaccines targeting norovirus and influenza, showcasing its ongoing commitment to research and development in the vaccine space.
Conversely, sales of Moderna's RSV vaccine, mRESVIA®, were only $10 million, falling short of expectations due to its late approval in the contracting season. The company experienced a decline in international sales compared to the previous year, attributed to the fulfillment of deferred orders. Additionally, despite a decrease in overall operating expenses, the cash position declined to $9.2 billion from $10.8 billion in the previous quarter, primarily due to increased research and development expenditures. These factors highlight ongoing challenges in market dynamics and product uptake.
linkNov 07, 2024 06:33:51
Moderna has announced the appointment of Abbas Hussain to its Board of Directors, effective October 2, 2024. Hussain brings over 35 years of experience in the healthcare sector, including his recent role as CEO of Vifor Pharma and significant leadership positions at GlaxoSmithKline. His extensive background in vaccine commercialization is expected to enhance Moderna's global commercialization efforts and contribute valuable insights as the company continues to innovate in mRNA medicine.
The leadership at Moderna expressed excitement about Hussain's addition to the board, highlighting his strategic expertise and operational experience in both emerging and mature markets. Hussain himself conveyed enthusiasm for joining a company that is at the forefront of medical innovations and expressed confidence in contributing to its future advancements. This move is seen as a positive step for Moderna as it aims to strengthen its commercial organization and expand its impact on public health.
linkOct 02, 2024 07:03:59
Moderna has showcased significant advancements in its vaccine pipeline, announcing positive Phase 3 results for its RSV and flu vaccines aimed at high-risk populations. The company plans to submit applications for its next-generation COVID vaccine and a combination flu/COVID vaccine in 2024, with a goal of achieving ten product approvals by 2027. Additionally, Moderna is implementing cost efficiencies to reduce its R&D expenses by $1.1 billion, reflecting a strategic shift to prioritize key projects and enhance commercial viability.
While Moderna's progress in vaccine development is promising, the company is also facing challenges. It has decided to discontinue five programs based on strategic prioritization, indicating a need to focus resources on more impactful initiatives. Furthermore, despite the positive outlook for its respiratory franchise, the company anticipates a significant reduction in overall R&D investment in the coming years, which may raise concerns about its long-term growth potential. Overall, Moderna's commitment to innovation and efficiency is clear, but navigating regulatory hurdles and market conditions remains critical.
linkSep 12, 2024 06:03:14
Moderna's Q2 2024 revenue fell to $241 million, with a net loss of $1.3 billion. The company received FDA approval for its RSV vaccine and reported positive data for its COVID-19 and flu vaccines. However, product sales expectations were revised down due to low EU sales and a competitive market. Despite a significant reduction in costs, the overall financial outlook remains cautious.
linkAug 01, 2024 06:31:37
Moderna welcomes David Rubenstein to its Board of Directors, bringing extensive investment and policy expertise. He replaces retiring director Stephen Berenson, while co-founder Robert Langer will also step down. Both will continue to advise the company. Rubenstein's appointment is seen as a positive move for Moderna's global growth strategy, although it marks the end of an era for two key figures in the company’s development.
linkJul 23, 2024 07:05:39
Moderna reports $167M in revenues, $1.2B net loss. Initiates new clinical studies, advances vaccine programs. Focus on AI tech for productivity. Expects $4B product sales in 2024. Decline in COVID-19 vaccine sales affects revenue. Cost of sales down, R&D expenses decrease. Net loss of $1.2B in Q1 2024 compared to $79M income in Q1 2023.
linkMay 02, 2024 06:31:17